Qynapse Highlights Accuracy of AI Tools for Alzheimer's Disease Progression

Qynapse has released new data demonstrating the accuracy of its AI-powered tools, QyScore and QyPredict, in predicting disease progression in preclinical Alzheimer's disease. Announced in a press release, the findings were presented at the Alzheimer's Association International Conference (AAIC).

QyScore is an FDA-cleared and CE-marked neuroimaging software platform that automates high-resolution segmentation of brain structures from MRI scans. It has shown higher segmentation accuracy and reliability compared to other established products. QyPredict, a predictive research-use-only platform, uses QyScore outputs to identify patients likely to experience clinical decline. The model accurately identified patients with preclinical Alzheimer's and mild cognitive impairment who were more likely to experience cognitive decline over 24 months.

Dr. James E Galvin from the University of Miami emphasized the importance of early identification of patients likely to experience cognitive decline for evaluating disease-modifying medications. Olivier Courrèges, CEO of Qynapse, expressed optimism about the role of imaging biomarkers and predictive modeling in improving patient selection and clinical trials.